Aurobindo Pharma, Novartis call off $1 billion deal with Sandoz
Deal mutually terminated as approval from U.S. FTC not obtained within anticipated timelines; Under the September 2018 pact, Aurobindo was to buy U.S. generic oral solids, dermatology businesses from Sandoz Inc.